Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 26-May 2015. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 138971000087112 | SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 96501000087111 | RSVAb SYNAGIS BI | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 96511000087113 | SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 97591000087116 | RSVAc SYNAGIS BI | fr | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway French module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | est un(e) (attribut) | médicament contenant palivizumab (produit médicinal) | false | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | a pour principe actif (attribut) | Respiratory syncytial virus monoclonal antibody | false | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Plays role | Passive immunity stimulant therapeutic role | true | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has presentation strength numerator unit | milligram (qualifier value) | true | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | est un(e) (attribut) | Product containing precisely palivizumab 100 milligram/1 vial powder for conventional release solution for injection (clinical drug) | true | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has precise active ingredient | Respiratory syncytial virus monoclonal antibody | true | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has presentation strength numerator value (attribute) | 100 | false | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has supplier | Boehringer Ingelheim (BI) Pharma KG (supplier) | true | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has basis of strength substance (attribute) | Respiratory syncytial virus monoclonal antibody | true | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has unit of presentation | Vial (unit of presentation) | true | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | a une forme pharmaceutique (attribut) | Powder for solution for injection | true | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Has presentation strength denominator unit (attribute) | Vial (unit of presentation) | true | Inferred relationship | Some | 1 | |
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| SYNAGIS 100 milligrams per milliliter powder for solution for injection Boehringer Ingelheim (BI) Pharma KG (real clinical drug) | Plays role | Antiviral therapeutic role | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
FHIR